HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Nab-Paclitaxel Proves More Beneficial Than Paclitaxel in Some Subsets of Breast Cancer

January 7th 2017

Nab-paclitaxel provides more benefits than paclitaxel for certain subsets of patients with breast cancer.

Prophylactic Treatment Reduces Neratinib-Related Toxicity in HER2+ Breast Cancer

January 5th 2017

A prophylactic treatment of loperamide plus budesonide reduced the rate of grade 3 diarrhea associated with neratinib.

Lapatinib Plus Whole-Brain Radiotherapy May Control Brain Metastases in HER2+ Breast Cancer

January 4th 2017

An investigation of the tyrosine kinase inhibitor lapatinib plus whole-brain radiotherapy has entered into a phase II trial in the treatment of patients with brain metastases from HER2-positive breast cancer.

MM-302 Falls Short in Phase II HER2+ Breast Cancer Trial

December 21st 2016

The phase II HERMIONE trial was halted after the antibody-drug conjugate MM-302 combined with trastuzumab failed to improve progression-free survival versus chemotherapy plus trastuzumab in patients with HER2-positive metastatic breast cancer who had previously received trastuzumab, pertuzumab, and ado-trastuzumab emtansine.

Dr. Prat on HER2-Enriched Subtype as Strong Predictor of HER2-Targeted Treatment

December 15th 2016

Aleix Prat, MD, PhD, head of the Department of Medical Oncology, the August Pi i Sunyer Biomedical Research Institute, discusses the results of the open-label PAMELA trial, in which the HER2-enriched subtype predicted pathologic complete response to targeted treatment in patients with HER2-positive, hormone receptor-positive breast cancer.

Dr. Rimawi on Neoadjuvant Estrogen Deprivation Therapy in HER2+ Breast Cancer

December 15th 2016

Mothaffar F. Rimawi, MD, associate professor and medical director at the Lester and Sue Smith Breast Center at the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, discusses the findings of the NSABP B-52 trial, which explored the addition of neoadjuvant estrogen deprivation therapy to docetaxel and carboplatin plus the HER2 inhibitors trastuzumab (Herceptin) and pertuzumab (Perjeta) as treatment for patients with HER2-positive breast cancer.

Dr. Alvarez on Updated Findings With Eribulin in Patients With HER2- Breast Cancer

December 13th 2016

Ricardo H. Alvarez, MD, MSc, director of Cancer Research, breast medical oncologist, Southeastern Regional Medical Center, Cancer Treatment Centers of America, discusses updated findings regarding the mechanism of action with eribulin mesylate (Halaven) and how it impacts patients with HER2-negative breast cancer.

Prophylactic Regimen Reduces Neratinib-Related Diarrhea in HER2+ Breast Cancer

December 9th 2016

Prophylactic treatment with the combination of loperamide and budesonide reduced the rate of grade ≥3 diarrhea associated with neratinib to 15% compared with 39.9% observed in the ExteNET trial.

Biomarker Analysis Shows Promise for Predicting Breast Cancer Response

December 9th 2016

A biomarker analysis of participants in a phase II breast cancer trial demonstrated potential for identifying tumor markers to predict susceptibility to specific therapies.

HER2-Enriched Breast Tumor Subtype Predicts Response to HER2 Dual Blockade

December 9th 2016

The HER2-enriched subtype of HER2-positive breast cancer is a strong predictor of sensitivity to dual HER2 blockade without the use of chemotherapy.

Hormonal Therapy Effectively Added to Dual HER2-Blockade in Phase II PERTAIN Study

December 8th 2016

The addition of an aromatase inhibitor (AI) to pertuzumab and trastuzumab improved progression-free survival by 3.09 months, when compared with trastuzumab plus an AI.

TILs Associated With Survival for Advanced HER2+ Breast Cancer

December 8th 2016

Higher levels of tumor-infiltrating lymphocytes were associated with improvements in overall survival for patients with advanced HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab in the phase III CLEOPATRA trial.

Dr. Carey on Ongoing Progress in HER2+ Breast Cancer

December 2nd 2016

Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses the ongoing progress with agents in development for the potential treatment of patients with HER2-positive breast cancer.

I-SPY 2 Paves the Way for Novel HER2-Targeted Agents in Breast Cancer

November 22nd 2016

There are a wide variety of novel agents currently being investigated in the neoadjuvant setting for patients with HER2-positive breast cancer.

Dr. Tripathy on Immunotherapy Potential in HER2-Positive Breast Cancer

November 19th 2016

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the potential role of immunotherapy in the treatment of patients with HER2-positive breast cancer.

Dr. Borgen on Successful Progress in HER2-Positive Breast Cancer

November 17th 2016

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses the successful progress seen in the treatment landscape of HER2-positive breast cancer.

Improved Patient Selection Needed to Advance HER2+ Breast Cancer Care

November 17th 2016

Immunotherapy and chemotherapy are options physicians should not dismiss for patients with HER2-positive breast cancer, according to Lisa Carey, MD, even with the available targeted agents trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine.

Dr. Tripathy on Neoadjuvant Agents for HER2+ Breast Cancer

November 16th 2016

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses agents that are available and in development in the neoadjuvant setting as treatments for patients with HER2-positive breast cancer.

Expert Sheds Light on Efficacy of Dual HER2-Directed Therapy

November 15th 2016

Dual HER2-directed therapy has demonstrated promising efficacy as a treatment approach for patients with breast cancer. Still, there remains a need for further research pertaining to therapies for HER2-positive patients who do do not meet the current criteria for this neoadjuvant regimen.

Dr. Anders on Systemic Agents for Patients With Breast Cancer and Brain Mets

November 15th 2016

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, at UNC-Chapel Hill, UNC Linebarger Comprehensive Cancer Center, discusses systemic agents available and in development for patients with breast cancer who also have brain metastases.